Breaking News

Pfizer Recalls Effexor XR and Venlafaxine HCl Lots

By Kristin Brooks | March 7, 2014

Pharmacist reports one bottle contained a Tikosyn capsule

Pfizer Inc. is recalling two lots of Effexor XR (venlafaxine HCl), 30-count and 90-count bottles of 150 mg extended-release capsules, as well as one lot of 90-count Greenstone LLC-branded Venlafaxine HCl 150 mg extended-release capsules. The recall is the result of a pharmacist report that one bottle of Pfizer’s Effexor XR contained one capsule of Tikosyn (dofetilide) 0.25mg among the Effexor XR capsules. According to the company, Pfizer has not received any other such reports, and these three lots are being voluntarily recalled as a precaution because they were packaged on the same line.
Effexor XR is an antidepressant indicated for the treatment of major depressive disorder, general anxiety disorder, social anxiety disorder, and panic disorder. Tikosyn is a Class III antiarrhythmic drug used to treat irregular heartbeat in patients with atrial fibrillation. According to the company, the use of Tikosyn by an Effexor XR/Venlafaxine HCl patient could potentially cause serious adverse health consequences that could be fatal.
This recall is at the patient level and involves Pfizer lot numbers V130142 and V130140, which both expire in October 2015, and Greenstone lot number V130014, which expires in August 2015. These products were distributed nationally to wholesalers, distributors, certain government agencies, patient assistance programs and retailers, such as pharmacies and hospitals. Customers are being notified by UPS next day mail, and Pfizer is arranging for the return of the recalled products.

blog comments powered by Disqus
  • Single-Use Clarification System for High-Density Cell Cultures

    Single-Use Clarification System for High-Density Cell Cultures

    Tjebbe van der Meer, Sartorius Stedim Biotech||June 2, 2015
    Continuous improvements in growth media and cell line viability have resulted in increased biomass concentrations in biopharmaceutical production processes, making the downstream purification step more challenging. Body feed filtration has proven to be a successful method of solving similar issues in other industries. This robust technology is now available as a harvesting solution for biotechnology applications.

  • Newsmakers: John Chiminski

    Newsmakers: John Chiminski

    May 6, 2015
    Catalent Completes $52M Expansion at Winchester, KY, Facility

  • Will All Tablets and Capsules Have On-Dose Physical Chemical Identifiers Soon?

    Will All Tablets and Capsules Have On-Dose Physical Chemical Identifiers Soon?

    Kent Mansfield , president TruTag Technologies, Inc.||April 1, 2015
    As the global problem of counterfeit and diverted drugs continues to grow worldwide, will our medicine soon carry secure identifiers woven into the very fabric of the drug product? Advancing technology is finally allowing drug makers the ability to implement on-dose authentication.